Jennifer A Mertz - Constellation Pharmaceuticals

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 43 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers

CANCER RESEARCHno. 15 (2024): 2501-2517

Cited0Views0WOSBibtex

Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

Andrew R. Conery,Richard C. Centore,Kerry L. Spillane,Nicole E. Follmer,Archana Bommi-Reddy,Charlie Hatton,Barbara M. Bryant,Patricia Greninger,Arnaud Amzallag,Cyril H. Benes,Jennifer A. Mertz,Robert J. Sims

crossref（2023）

Cited0Views0Bibtex

Supporting Data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Abstract ND08: Discovery of FX-909, a First-in-class Inverse Agonist of the Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Lineage Transcription Factor, to Potentially Treat Patients with the Luminal Subtype of Advanced Urothelial Cancer (UC)

Robert Sims,Jennifer A. Mertz,Jonathan E. Wilson, James E. Audia,Kaylyn E. Williamson, Yong Li,Miljan Kuljanin, Will W. Motely,Byron DeLaBarre,Michaela Bowden,Jacob I. Stuckey

Cancer Researchno. 7_Supplement (2023)

Cited0Views0Bibtex

Abstract 2802: Development of a Surrogate Tissue Pharmacodynamic (PD) Assay for Clinical Use with FX-909, a Novel Inhibitor of the Urothelial Luminal Lineage Transcription Factor Peroxisome Proliferator-Activated Receptor Gamma (PPARG)

Jennifer A. Mertz,Stefan A. Kirov,Kaylyn E. Williamson, Marton Munz,Robert J. Sims,Michaela Bowden

Cancer Researchno. 7_Supplement (2023): 2802-2802

Cited0Views0Bibtex

Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors is Determined by the Apoptotic Response

crossref（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn